candesartan has been researched along with Chronic Hepatitis C in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd Alla, MD | 1 |
| Eid, EMM | 1 |
| Soliman, AIA | 1 |
| Elhawary, MA | 1 |
| Kilany, YF | 1 |
| Abd-Almonaem, G | 1 |
| Bayoumi, SS | 1 |
| Moursy, MRA | 1 |
| Al-Zaem, FAM | 1 |
1 trial available for candesartan and Chronic Hepatitis C
| Article | Year |
|---|---|
PORTAL HYPERTENSION TREATMENT WITH CANDESARTAN PLUS PROPRANOLOL FOR NINE MONTHS RESTORES NORMAL PORTAL CIRCULATION HEMODYNAMIC PATTERN.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administration Schedule; Drug Ther | 2016 |